Jove
Visualize
联系我们
JoVE
x logofacebook logolinkedin logoyoutube logo
关于 JoVE
概览领导团队博客JoVE 帮助中心
作者
出版流程编辑委员会范围与政策同行评审常见问题投稿
图书馆员
用户评价订阅访问资源图书馆顾问委员会常见问题
研究
JoVE JournalMethods CollectionsJoVE Encyclopedia of Experiments存档
教育
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab Manual教师资源中心教师网站
使用条款与条件
隐私政策
政策

相关概念视频

Cancer Survival Analysis01:21

Cancer Survival Analysis

328
Cancer survival analysis focuses on quantifying and interpreting the time from a key starting point, such as diagnosis or the initiation of treatment, to a specific endpoint, such as remission or death. This analysis provides critical insights into treatment effectiveness and factors that influence patient outcomes, helping to shape clinical decisions and guide prognostic evaluations. A cornerstone of oncology research, survival analysis tackles the challenges of skewed, non-normally...
328
Comparing the Survival Analysis of Two or More Groups01:20

Comparing the Survival Analysis of Two or More Groups

154
Survival analysis is a cornerstone of medical research, used to evaluate the time until an event of interest occurs, such as death, disease recurrence, or recovery. Unlike standard statistical methods, survival analysis is particularly adept at handling censored data—instances where the event has not occurred for some participants by the end of the study or remains unobserved. To address these unique challenges, specialized techniques like the Kaplan-Meier estimator, log-rank test, and...
154
Assumptions of Survival Analysis01:15

Assumptions of Survival Analysis

97
Survival models analyze the time until one or more events occur, such as death in biological organisms or failure in mechanical systems. These models are widely used across fields like medicine, biology, engineering, and public health to study time-to-event phenomena. To ensure accurate results, survival analysis relies on key assumptions and careful study design.
97
Introduction To Survival Analysis01:18

Introduction To Survival Analysis

184
Survival analysis is a statistical method used to study time-to-event data, where the "event" might represent outcomes like death, disease relapse, system failure, or recovery. A unique feature of survival data is censoring, which occurs when the event of interest has not been observed for some individuals during the study period. This requires specialized techniques to handle incomplete data effectively.
The primary goal of survival analysis is to estimate survival time—the time...
184

您也可能阅读

相关文章

通过共同作者、期刊和引用图与本文相关的文章。

排序
Same author

Comparative analysis of pelvic/sacral versus vertebral chordomas in the US from 2000 to 2020.

European spine journal : official publication of the European Spine Society, the European Spinal Deformity Society, and the European Section of the Cervical Spine Research Society·2026
Same author

Acute Finger Ischemia Evaluated With Point-Of-Care-Ultrasound and Diagnosed With Concurrent Polycythemia Vera, Antiphospholipid Syndrome, and Tobacco Use.

Clinical case reports·2026
Same author

Midterm Outcomes Following Repair of Complex Meniscus Tears: A Retrospective Analysis of Failure Risk and Postoperative Complications.

The journal of knee surgery·2026
Same author

Use of pelvic incidence to predict proximal junctional failure in long-segment spinal fusion.

Journal of neurosurgery. Spine·2026
Same author

Pelvic Inflammatory Disease With Presumptive Tubo-Ovarian Abscess Presenting With Rectal Spasm.

Case reports in obstetrics and gynecology·2026
Same author

Barriers to Receiving Proton-Craniospinal Irradiation for Pediatric Medulloblastoma Patients at a Rural Tertiary Care Center.

Cureus·2026

相关实验视频

Updated: Jun 7, 2025

Author Spotlight: Unveiling Transmembrane Protein Family-Related Markers in Gastric Cancer and Implications for Targeted Therapies
07:47

Author Spotlight: Unveiling Transmembrane Protein Family-Related Markers in Gastric Cancer and Implications for Targeted Therapies

Published on: September 15, 2023

1.4K

亚当瘤:基于SEER的流行病学分析

Kevin E Agner1, Michael C Larkins2,3

  • 1The Ohio State University College of Medicine, 370 W. 9 Avenue, Columbus, OH 43210 USA.

Indian journal of surgical oncology
|November 18, 2024
PubMed
概括
此摘要是机器生成的。

年轻患者被诊断患有罕见的骨癌阿达曼蒂诺马 (AD),长期生存率提高,疾病更局部. 诊断时的年龄是影响这种罕见癌症结果的关键因素.

关键词:
人类瘤 (Adamantinoma) 是一个人类瘤.癌症流行病学 癌症流行病学儿科瘤学 儿科瘤学手术瘤学手术瘤学

更多相关视频

Lineage Tracing and Clonal Analysis in Developing Cerebral Cortex Using Mosaic Analysis with Double Markers MADM
09:25

Lineage Tracing and Clonal Analysis in Developing Cerebral Cortex Using Mosaic Analysis with Double Markers MADM

Published on: May 8, 2020

10.6K
Systematic Assessment of Mammalian Skull Specimens for Dental and Temporomandibular Joint Pathology
07:26

Systematic Assessment of Mammalian Skull Specimens for Dental and Temporomandibular Joint Pathology

Published on: August 22, 2022

1.3K

相关实验视频

Last Updated: Jun 7, 2025

Author Spotlight: Unveiling Transmembrane Protein Family-Related Markers in Gastric Cancer and Implications for Targeted Therapies
07:47

Author Spotlight: Unveiling Transmembrane Protein Family-Related Markers in Gastric Cancer and Implications for Targeted Therapies

Published on: September 15, 2023

1.4K
Lineage Tracing and Clonal Analysis in Developing Cerebral Cortex Using Mosaic Analysis with Double Markers MADM
09:25

Lineage Tracing and Clonal Analysis in Developing Cerebral Cortex Using Mosaic Analysis with Double Markers MADM

Published on: May 8, 2020

10.6K
Systematic Assessment of Mammalian Skull Specimens for Dental and Temporomandibular Joint Pathology
07:26

Systematic Assessment of Mammalian Skull Specimens for Dental and Temporomandibular Joint Pathology

Published on: August 22, 2022

1.3K

科学领域:

  • 在瘤学瘤学.
  • 整形瘤学 整形瘤学
  • 癌症流行病学 癌症流行病学

背景情况:

  • 亚当瘤 (AD) 是一种非常罕见的原发性骨恶性瘤,占所有骨瘤的0.5%以下.
  • 缺乏确定的治疗指南和AD的综合长期存活数据.
  • 了解预后因素对于改善罕见癌症患者的治疗结果至关重要.

研究的目的:

  • 在被诊断为阿达曼蒂诺马的患者中调查长期 (20年) 整体存活率 (OS).
  • 确定影响阿兹海默症患者20年生存期的人口结构和治疗变量.
  • 探索诊断时的年龄与疾病呈现 (局部与远程) 之间的关系.

主要方法:

  • 利用监测,流行病学和最终结果 (SEER) 计划数据库进行患者识别.
  • 分析了74名被诊断为初级阿达曼蒂诺马的患者的数据 (ICD-O-3代码9261/3).
  • 采用Fisher的精确测试用于人口和治疗变量分析以及对20年OS评估的日志排名分析.

主要成果:

  • 诊断时年轻的年龄 (<25岁) 与增加的20年整体存活率 (HR=0.28,p=0.028) 有意义地相关.
  • 诊断时40岁以上的患者的20年生存率 (46%) 与40岁或更年轻的患者 (96%,p=0.005) 相比显著下降.
  • 年轻的患者 (≤40岁) 更有可能出现局部疾病 (p=0.017),而老年患者 (>40岁) 患有更高比例的远程疾病.

结论:

  • 诊断时年轻的年龄是阿达曼瘤长期存活的显著积极预后因素.
  • 年龄影响了生存结果和局部与远程疾病呈现的可能性.
  • 需要进一步的基于人口的研究来克服罕见癌症数据收集和编码的局限性.